Pieternella M Houtman
Overview
Explore the profile of Pieternella M Houtman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arends S, van der Veer E, Kamps F, Houtman P, Bos R, Bootsma H, et al.
Clin Exp Rheumatol
. 2015 Mar;
33(2):174-80.
PMID: 25797228
Objectives: Tumour necrosis factor-alpha (TNF-α) blocking agents are very effective in controlling systemic inflammation and improving clinical assessments in ankylosing spondylitis (AS). In view of potential side effects and high...
2.
Arends S, Hofman M, Kamsma Y, van der Veer E, Houtman P, Kallenberg C, et al.
Arthritis Res Ther
. 2013 Aug;
15(4):R99.
PMID: 23971767
Introduction: The aim of this study was to investigate the construct validity and test-retest reliability of the International Physical Activity Questionnaire (IPAQ; long form) and the Short QUestionnaire to Assess...
3.
Wink F, Arends S, McKenna S, Houtman P, Brouwer E, Spoorenberg A
PLoS One
. 2013 Feb;
8(2):e55912.
PMID: 23418474
Objective: The Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire is a disease- specific instrument developed to measure quality of life (QoL) in patients with psoriatic arthritis (PsA). The aim of...
4.
5.
Arends S, Spoorenberg A, Houtman P, Leijsma M, Bos R, Kallenberg C, et al.
Arthritis Res Ther
. 2012 May;
14(2):R98.
PMID: 22546520
Introduction: The aim of this study was to investigate the effect of three years of tumor necrosis factor-alpha (TNF-α) blocking therapy on bone turnover as well as to analyze the...
6.
de Punder Y, Fransen J, Kievit W, Houtman P, Visser H, van de Laar M, et al.
Rheumatology (Oxford)
. 2012 Apr;
51(9):1610-7.
PMID: 22539487
Objectives: To evaluate the prevalence of clinical remission and minimal disease activity according to the ACR/European League Against Rheumatism (EULAR) remission, DAS-28 <2.6 and minimal disease activity (MDA) criteria, and...
7.
Balink H, Houtman P, Collins J
Clin Rheumatol
. 2011 Jun;
30(8):1139-41.
PMID: 21701795
No abstract available.
8.
Arends S, Brouwer E, van der Veer E, Groen H, Leijsma M, Houtman P, et al.
Arthritis Res Ther
. 2011 Jun;
13(3):R94.
PMID: 21689401
Introduction: Identifying ankylosing spondylitis (AS) patients who are likely to benefit from tumor necrosis factor-alpha (TNF-α) blocking therapy is important, especially in view of the costs and potential side effects...
9.
Arends S, van der Veer E, Groen H, Houtman P, Jansen T, Leijsma M, et al.
J Rheumatol
. 2011 Jun;
38(8):1644-50.
PMID: 21632677
Objective: To investigate whether level of serum matrix metalloproteinase-3 (MMP-3) can serve as a biomarker for monitoring and predicting response to etanercept treatment in patients with ankylosing spondylitis (AS) in...
10.
Wink F, Houtman P, Jansen T
Clin Rheumatol
. 2010 Nov;
30(2):293-300.
PMID: 21053035
Cryoglobulinaemia associated with systemic vasculitis mediated by immune complexes is a rare combination. These immune complexes are composed of immunoglobulins and precipitate when exposed to cold temperature. Cryoglobulinaemic vasculitis, treated...